Acquired haemophilia A in southern Switzerland from 2013 to 2019: a case series
暂无分享,去创建一个
G. Stussi | J. K. Kremer Hovinga | B. Gerber | E. Bianchi | R. Monotti | D. Valente | A. Ruberti | D. Rossi | Elena Galfetti | Pamella Paul | E. Fernandes | Federico Nappi | Aurora Vettese | S. Regazzoni
[1] J. Oldenburg,et al. Investigating potential mechanisms underlying FVIII inhibition in acquired hemophilia A associated with mRNA COVID‐19 vaccines , 2022, Journal of Thrombosis and Haemostasis.
[2] W. Korte,et al. The statistical risk of diagnosing coincidental acquired hemophilia A following anti‐SARS‐CoV‐2 vaccination , 2021, Journal of Thrombosis and Haemostasis.
[3] S. Lacroix-Desmazes,et al. Acquired Hemophilia A in IgG4-Related Disease: Case Report, Immunopathogenic Study, and Review of the Literature , 2020, Frontiers in Immunology.
[4] L. Alberio,et al. Management of bleeding events and invasive procedures in patients with haemophilia A without inhibitors treated with emicizumab. , 2020, Swiss medical weekly.
[5] P. Knöbl,et al. Should emicizumab be used in patients with acquired hemophilia A? , 2020, Journal of thrombosis and haemostasis : JTH.
[6] A. Tiede,et al. The rising incidence of acquired haemophilia A in Germany , 2020, Haemophilia : the official journal of the World Federation of Hemophilia.
[7] A. Tiede,et al. Reduced-intensity, risk factor–stratified immunosuppression for acquired hemophilia A: single-center observational study , 2020, Annals of Hematology.
[8] A. Tiede,et al. Acquired bleeding disorders , 2020, Haemophilia : the official journal of the World Federation of Hemophilia.
[9] P. Giangrande,et al. International recommendations on the diagnosis and treatment of acquired hemophilia A , 2020, Haematologica.
[10] P. Knöbl,et al. Bleeding and Response to Hemostatic Therapy in Acquired Hemophilia A (AHA): Results from the GTH-AH 01/2010 Study. , 2020, Blood.
[11] J. Goetze,et al. Unexpected, isolated activated partial thromboplastin time prolongation: A practical mini‐review , 2020, European journal of haematology.
[12] C. Königs,et al. Cross‐reacting inhibitors against recombinant porcine factor VIII in acquired hemophilia A: Data from the GTH‐AH 01/2010 Study , 2020, Journal of thrombosis and haemostasis : JTH.
[13] P. Giangrande,et al. Clinical evaluation of bleeds and response to haemostatic treatment in patients with acquired haemophilia: A global expert consensus statement , 2019, Haemophilia : the official journal of the World Federation of Hemophilia.
[14] J. Shaw,et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9th edition. , 2019, Diabetes research and clinical practice.
[15] A. Pottegård,et al. Use of prescription drugs in the older adult population—a nationwide pharmacoepidemiological study , 2019, European Journal of Clinical Pharmacology.
[16] A. Bonnefoy,et al. Relapse pattern and long‐term outcomes in subjects with acquired haemophilia A , 2019, Haemophilia : the official journal of the World Federation of Hemophilia.
[17] C. Santoro,et al. Low dose of aPCC after the initial treatment in acquired haemophilia A is useful to reduce bleeding relapses: Data from the FAIR registry. , 2019, Thrombosis research.
[18] R. Nisenbaum,et al. Retrospective review of Acquired Haemophilia A from the largest Canadian Haemophilia treatment centre , 2018, Haemophilia : the official journal of the World Federation of Hemophilia.
[19] C. Königs,et al. Frequency and epitope specificity of anti-factor VIII C1 domain antibodies in acquired and congenital hemophilia A. , 2017, Blood.
[20] Y. Komiyama,et al. New formulas for mixing test to discriminate between lupus anticoagulant and acquired hemophilia A. , 2016, Thrombosis research.
[21] A. Koch,et al. Anti-factor VIII IgA as a potential marker of poor prognosis in acquired hemophilia A: results from the GTH-AH 01/2010 study. , 2016, Blood.
[22] W. Tsay,et al. A study of 65 patients with acquired hemophilia A in Taiwan. , 2015, Journal of the Formosan Medical Association = Taiwan yi zhi.
[23] E. Gomperts,et al. Efficacy and safety of OBI‐1, an antihaemophilic factor VIII (recombinant), porcine sequence, in subjects with acquired haemophilia A , 2015, Haemophilia : the official journal of the World Federation of Hemophilia.
[24] R. Greil,et al. Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01/2010 study. , 2015, Blood.
[25] J. Goudemand,et al. Outcome of acquired haemophilia in France: the prospective SACHA (Surveillance des Auto antiCorps au cours de l'Hémophilie Acquise) registry , 2013, Haemophilia : the official journal of the World Federation of Hemophilia.
[26] F. Pellegrini,et al. Pregnancy‐associated acquired haemophilia A: results from the European Acquired Haemophilia (EACH2) registry , 2012, BJOG : an international journal of obstetrics and gynaecology.
[27] C. Granier,et al. The IgG autoimmune response in postpartum acquired hemophilia A targets mainly the A1a1 domain of FVIII , 2012, Journal of thrombosis and haemostasis : JTH.
[28] F. Pellegrini,et al. Immunosuppression for acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). , 2012, Blood.
[29] F. Pellegrini,et al. Management of bleeding in acquired hemophilia A: results from the European Acquired Haemophilia (EACH2) Registry. , 2012, Blood.
[30] J. Esser,et al. Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2) , 2012, Journal of thrombosis and haemostasis : JTH.
[31] J. Oldenburg,et al. Genetic markers in acquired haemophilia , 2010, Haemophilia : the official journal of the World Federation of Hemophilia.
[32] A. Ganser,et al. Acquired haemophilia caused by non-haemophilic factor VIII gene variants , 2010, Annals of Hematology.
[33] T. Baglin,et al. Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors' Organisation. , 2007, Blood.
[34] M. Reding. Immunological aspects of inhibitor development , 2006, Haemophilia : the official journal of the World Federation of Hemophilia.
[35] S. Schulman,et al. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patients , 2005, Journal of thrombosis and haemostasis : JTH.
[36] J. Delgado,et al. Acquired Haemophilia: Review and Meta‐Analysis Focused on Therapy and Prognostic Factors , 2003, British journal of haematology.
[37] C. Kitchens,et al. Acquired hemophilia. A natural history study of 16 patients with factor VIII inhibitors receiving little or no therapy. , 1987, Archives of internal medicine.
[38] M. Modan,et al. Detection and Quantitative Evaluation of Lupus Circulating Anticoagulant Activity , 1987, Thrombosis and Haemostasis.
[39] K. Lechner,et al. A Survey of 215 Non-Hemophilic Patients with Inhibitors to Factor VIII , 1981, Thrombosis and Haemostasis.